title: Th17, gut, and HIV: therapeutic implications.
abstract: OBJECTIVE
  The purpose of this review is to discuss the apparent impact of persistent-immune activation and inflammation on morbidity and mortality among treated HIV-infected individuals, to explore the potential role of Th17 T-cell depletion in this process, and to discuss potential-therapeutic implications.
  
  
  RESULTS
  Although the vast majority of HIV-infected individuals can now achieve and maintain viral suppression with modern-antiretroviral therapy (ART), their life expectancy remains much shorter than the general population and they continue to be at much higher risk for non-AIDS-associated diseases commonly associated with aging (non-AIDS-associated cancer, cardiovascular disease, etc). Abnormal levels of immune activation and inflammation persist despite sustained viral suppression and may drive these clinical events. Although the causes of persistent-immune activation remain incompletely characterized, persistent low-level HIV replication and/or release from latently infected cells in gut-associated lymphoid tissue (GALT) and microbial translocation probably play a major role. Failure to restore Th17 cells in GALT during ART might impair both the recovery of the gut mucosal barrier and the clearance of microbial products.
  
  
  CONCLUSIONS
  Insights from recent-pathogenesis studies might suggest novel-therapeutic approaches designed to restore Th17 cells in GALT, thereby decreasing microbial translocation, immune activation, and ultimately morbidity and mortality during treated HIV infection.
authors.affiliation: Positive Health Program, San Francisco General Hospital, University of California-San Francisco, 995 Potrero Avenue, San Francisco, CA 94110, USA. phunt@php.ucsf.edu
authors.forename: Peter W
authors.initials: PW
authors.lastname: Hunt
mesh_terms: D019380:Anti-HIV Agents / Q000627:therapeutic use; D001419:Bacteria / Q000276:immunology / Q000472:pathogenicity; D018988:Bacterial Translocation; D006678:HIV / Q000276:immunology* / Q000472:pathogenicity; D015658:HIV Infections / Q000276:immunology* / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D007249:Inflammation / Q000276:immunology / Q000473:pathology; D007413:Intestinal Mucosa / Q000276:immunology* / Q000473:pathology; D006377:T-Lymphocytes, Helper-Inducer / Q000276:immunology*
chemical_list: D019380:Anti-HIV Agents